-
Article
Thank private risk-taking, not public funding, for Covid-19 vaccines, therapies
04.05.2021
As they see it, the federal government invested in the research that led to today’s vaccines so the private companies behind them shouldn’t benefit from intellectual property protections. That argument is as misinformed as it is dangerous.
-
Article
Opinion: Intellectual property rights are not delaying coronavirus vaccines
03.15.2021
OP ED - WASHINGTON POST
-
Statement
FINAL NIST Oral Testimony – John Stanford, Incubate
02.25.2021
We're here today to lend our strong support to the proposed clarification of the appropriate use of "march-in" authority under Bayh Dole. This authority was never intended to be used a price-control mechanism, as such an interpretation would destabilize the IP protections that drive America's global biopharmaceutical leadership
-
Blog
Mergers and Acquisitions: A Key Driver of VC Investment in Healthcare
02.18.2021
The drug pricing debate is a worthy one. We have to have open discussions about maximizing innovation and access. But half-written reports from a region that is home to the economic benefits of this industry do little to move that debate forward.
-
Statement
Bayh-Dole Coalition Urges the Biden Administration to Preserve the Bayh-Dole Act
02.10.2021
PRESS RELEASE
-
Article
March-In is Not the Answer
01.28.2021
There is one strategy, however, that is likely to make things worse; overriding patents on drugs developed with the help of federally funded research. This so-called "march in" option is not a good idea.
-
Statement
Most Favored Nation (MFN) Model Interim Final Rule with Comment Period
01.26.2021
Incubate writes to share our strong concerns with the interim final rule (IFR) implementing the Most Favored Nation (MFN) Model. We request the Biden Administration withdraw this rule.
-
Infographic
-
Statement
Venture Capitalist Letter Addressing President Trump’s MFN EO
08.21.2020
early stage life sciences community, write in strong opposition to the recently signed Executive Order (EO), Lowering Drug Prices by Putting America First.
-
Article
Ensuring U.S. Biopharmaceutical Competitiveness
07.11.2020
By Stephen Ezell, Information Technology and Innovation Foundation
Resources
